HOME >> BIOLOGY >> NEWS
Genomic signatures identify targeted therapies for lung cancer

DURHAM, N.C. Any number of things can go wrong in the cells of the body to cause cancer -- and clinicians can't tell by just looking at a tumor what exactly triggered the once normal cells to turn cancerous.

New tests developed by researchers at Duke University can determine the precise patterns among thousands of genes to identify the cascade of events, or pathways, that led to the cancer.

These "genomic signatures" will give clinicians the tools they need to pursue alternatives to the traditional blunt force of chemotherapy. Following this test, patients might be treated with drugs that specifically target the faulty pathway, the researchers said.

"Traditional chemotherapy is not always effective," said Anil Potti, M.D., the study's lead investigator and an assistant professor of medicine in the Duke Institute for Genome Sciences & Policy. "Even when we are able to match the right chemotherapy with the right patient, 70 percent of patients with lung cancer may not respond to therapy. We need to take a different approach to those patients, and that is where these targeted therapeutics come in."

Potti and colleagues presented their findings on Sunday, June 3, at the annual meeting of the American Society for Clinical Oncology, in Chicago. The work was funded by the Jimmy V Foundation and the National Institutes of Health.

Mutations in individual cancer-causing genes, called oncogenes, set off a cascade of changes in the activity of hundreds of other interacting genes -- either increasing or decreasing their activity.

Rather than looking at each of these oncogenes individually, this new method presents a more global view by identifying the pathway encompassing all of the gene mutations that could have caused that cancer, Potti said.

The genomic test can theoretically apply to any cancer, but the Duke team focused on lung cancer because the survival rate is just 15 percent. Lung cancer now kil
'"/>

Contact: Marla Vacek Broadfoot
marla.broadfoot@duke.edu
919-660-1306
Duke University Medical Center
2-Jun-2007


Page: 1 2

Related biology news :

1. Genomics study provides insight into the evolution of unique human traits
2. Genomic analysis uncovers new targets for HIV vaccine
3. Psychiatric Genomics Center established at Cold Spring Harbor Laboratory
4. NYUs Center for Comparative Functional Genomics part of $57 million MOD-ENCODE consortium
5. Genomic test could help detect radioactivity exposure from terrorist attacks
6. Elsevier launches new journal, Marine Genomics
7. Genomics throws species definition in question for microbes
8. Genomic variation easier to identify with UCSD/Brown software
9. Springer adds Genomic Medicine to biomedical publishing portfolio
10. Genomic firestorms underlie aggressive breast cancer progression
11. Genomic comparison of lactic acid bacteria published

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... ... phase 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute ... Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research ...
(Date:7/1/2020)... SOMERSET, N.J. (PRWEB) , ... July 01, 2020 ... ... today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility ... with the company’s existing Japanese clinical supply facility located in Kakegawa, the new ...
(Date:6/28/2020)... (PRWEB) , ... June 25, ... ... of enterprise software solutions for biopharmaceutical R&D, today announced that it has ... developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management and ... it did not take off as quickly as people initially expected, and where eSource ... capturing data electronically for clinical trials and then repurposing it for downstream analysis, at ...
(Date:7/18/2020)... ... 16, 2020 , ... After research model surgery and catheter implantation, the long ... only the beginning of a successful study, while protecting and accessing the catheter or ... Head of Surgery from Envigo in a live webinar on ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... announces a significant expansion of laboratory operations through its COVID-19 testing service, ... testing programs. , Bode-CARES provides a turnkey solution that includes ...
(Date:7/7/2020)... DIEGO (PRWEB) , ... July 06, 2020 , ... R3 ... new program featuring up to 200 million stem cells. Depending on the patient's condition, ... seniors in the US will die having some form of Alzheimers dementia, and the ...
Breaking Biology Technology:
Cached News: